While high FABP7 expression has been linked to poor prognosis in glioma cancers in the existing literature, our data suggest that its role varies between LGG and GBM, reflecting distinct prognostic implications and immune interactions due to the generally different molecular and clinical characteristics of these tumor types [61,62]. Here, FABP7 is linked to glioblastoma.